115 results
Page 2 of 6
6-K
EX-99.2
ik38xx7pg
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
m9m32hmw8ggmk5tb43ql
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
EX-99.1
i52zm0n5
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
xf6qcbs
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
ch4n8g hh9
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
424B7
ojd 7icc7
3 Mar 22
Prospectus with selling stockholder info
4:43pm
F-3
8lq7nyqg 87a703ko2yn
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.1
e777y
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
zh47c05ep0egrnj
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
ryptaz 6wm66lf3cz2q1
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
EX-99.1
ltkvwb o78
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
424B7
s56 0u4za82w9
23 Nov 21
Prospectus with selling stockholder info
4:06pm
6-K
EX-99.2
b9jxbe9e 91skn
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.1
5hdi5vefo7a9
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
F-3
0vxk2 p93veb
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K
EX-99.2
r0h8m8dx bj1n7s4j
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.3
vhx4iam1
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am